The Efficacy and Improvement Methods of Multi-Kinase Inhibitors in the Treatment of Liver Cancer

Abstract

Liver cancer is a malignant tumor with an extremely high fatality rate worldwide, and traditional treatment methods have significant limitations. This thesis systematically explores the application of multi-kinase inhibitors in the treatment of liver cancer and deeply analyzes its dual mechanism of action: inhibiting tumor angiogenesis by blocking signaling pathways such as VEGF and PDGF, and simultaneously interfering with pathways such as MAPK to curb the proliferation of tumor cells. Based on key clinical research data such as SHARP and REFLECT, the survival benefits of monotherapy with drugs such as sorafenib and lenvatinib were elaborated in detail. The median survival period increased to 10.7-13.6 months, but the problems of drug resistance and adverse reactions were prominent. Combined immunotherapy and local treatment show the potential for synergistic enhancement. Studies have confirmed that screening for advantageous populations such as FGFR mutations through genetic testing can significantly improve the accuracy of treatment. This article aims to provide a comprehensive theoretical basis and innovative strategies for optimizing targeted therapy regimens for liver cancer and promoting clinical practice.